Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Eton Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts rate Eton Pharmaceuticals a “Moderate Buy”: Five of six covering brokerages recommend buying the stock, with an average 12-month price target of $79.75.
  • The company reported quarterly EPS of $0.50, above the $0.31 consensus estimate, and revenue of $57.93 million versus expectations of $41.98 million.
  • Company insiders sold 82,666 shares worth about $5.05 million during the last quarter; insiders retain 16.49% ownership.
  • Five stocks to consider instead of Eton Pharmaceuticals.

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $79.75.

A number of equities analysts have issued reports on the company. Canaccord Genuity Group increased their target price on Eton Pharmaceuticals from $68.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, November 6th. HC Wainwright lifted their price target on Eton Pharmaceuticals from $70.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, November 6th. Zacks Research lowered Eton Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 10th. Weiss Ratings upgraded Eton Pharmaceuticals from a "hold (c)" rating to a "buy (b-)" rating in a report on Monday, November 9th. Finally, B. Riley Financial upped their price objective on Eton Pharmaceuticals from $70.00 to $81.00 and gave the stock a "buy" rating in a research report on Tuesday, November 10th.

Get Our Latest Stock Analysis on ETON

Eton Pharmaceuticals Stock Down 0.2%

Shares of ETON stock opened at $63.83 on Friday. The firm has a fifty day moving average of $55.37 and a 200-day moving average of $37.96. The company has a quick ratio of 1.58, a current ratio of 1.79 and a debt-to-equity ratio of 0.13. Eton Pharmaceuticals has a 12-month low of $14.27 and a 12-month high of $70.64. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 42.27 and a beta of 0.89.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.19. The business had revenue of $57.93 million for the quarter, compared to analyst estimates of $41.98 million. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 104.82%. As a group, equities research analysts predict that Eton Pharmaceuticals will post 1.54 earnings per share for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider Ipek Erdogan-Trinkaus sold 3,500 shares of the business's stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $67.41, for a total value of $235,935.00. Following the sale, the insider owned 4,081 shares in the company, valued at approximately $275,100.21. The trade was a 46.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Paul V. Maier sold 50,000 shares of the company's stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares of the company's stock, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 82,666 shares of company stock valued at $5,045,607. 16.49% of the stock is owned by insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds have recently made changes to their positions in ETON. Hsbc Holdings PLC acquired a new stake in shares of Eton Pharmaceuticals in the second quarter valued at about $1,531,000. Bank of New York Mellon Corp bought a new stake in Eton Pharmaceuticals during the second quarter worth about $4,281,000. Squarepoint Ops LLC acquired a new position in Eton Pharmaceuticals during the second quarter valued at approximately $2,156,000. Jefferies Financial Group Inc. acquired a new position in Eton Pharmaceuticals during the second quarter valued at approximately $1,232,000. Finally, Bank of Nova Scotia acquired a new position in Eton Pharmaceuticals during the second quarter valued at approximately $623,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

(Get Free Report)

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company's products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.

Recommended Stories

Analyst Recommendations for Eton Pharmaceuticals (NASDAQ:ETON)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eton Pharmaceuticals Right Now?

Before you consider Eton Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.

While Eton Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines